Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nat Rev Clin Oncol
.
2022 Nov;19(11):744.
doi: 10.1038/s41571-022-00680-8.
Authors
Alissa J Cooper
1
,
Lecia V Sequist
1
,
Jessica J Lin
2
Affiliations
1
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
2
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. jjlin1@partners.org.
PMID:
35971001
DOI:
10.1038/s41571-022-00680-8
No abstract available
Publication types
Published Erratum